Vilya, a biotechnology firm based in Seattle, WA, has expanded its Series A funding to $71M.

The funding round was led by ARCH Venture Partners with participation from NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures. Menlo Ventures’ Partner Greg Yap has also joined the Vilya board.

The funds will be used to accelerate the advancement of Vilya’s proprietary computational drug design and development platform, along with its pipeline of novel macrocycles aimed at precisely targeting disease biology.

Vilya, led by CEO Cyrus Harmon, Ph.D., utilizes advanced machine learning and generative AI to explore uncharted chemical space and design de novo molecular structures. The company, which operates in Seattle and South San Francisco, focuses on previously challenging therapeutic targets.

The leadership team includes Chief Scientific Officer Katerina Leftheris, Ph.D., Co-Founder & CTO Patrick Salveson, Ph.D., and Co-Founder & VP of Business Development Inca Dieterich, Ph.D.